July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
Authors of a literature review note the high prevalence of liver disease among people with HIV and recommend a step-by-step approach to management.
Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.
HIV-positive donor, HIV-negative recipient; continuum of care after incarceration in U.S.; reduced bone mineral density among men with HIV under 50; discouraging anti-inflammatory findings for an antiplatelet agent.
Despite being cured of hepatitis C, "patients with advanced liver disease may still be at considerable risk of [developing symptoms associated with cirrhosis] and liver cancer," according to researchers in the Target Consortium.
Researchers at the University of Toronto conducted an intensive review of 37 published studies in which interferon was used as treatment for HCV infection. Among participants who were cured, 3% subsequently developed liver cancer. Among participants ...
Doctors in Barcelona recently reported an unexpected increase in liver cancer recurrence in people who had been or who are being treated for chronic hepatitis C virus (HCV) infection with new potent all-oral medicines called direct acting antivirals ...
Spurred by reports from other cities, doctors in Bologna, Italy, have reviewed their database to assess possible risk factors for liver cancer development and recurrence in 344 participants who were treated for hepatitis C virus (HCV) infection with ...